Displaying 241 - 252 of 275
Metabolism, Alcohol & Toxicity
4

Intercept: Emerging trends in the care pathway for patients with NASH - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
4

Intercept: Emerging trends in the care pathway for patients with NASH - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
4

Intercept: Emerging trends in the care pathway for patients with NASH - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
4

Intercept: Emerging trends in the care pathway for patients with NASH - Digital ILC 2020

View
General Hepatology
6

Intercept: FXR agonism in clinical practice: new perspectives from the real-world experience in PBC - Digital ILC 2020

View
General Hepatology
6

Intercept: FXR agonism in clinical practice: new perspectives from the real-world experience in PBC - Digital ILC 2020

View
General Hepatology
6

Intercept: FXR agonism in clinical practice: new perspectives from the real-world experience in PBC - Digital ILC 2020

View
General Hepatology
6

Intercept: FXR agonism in clinical practice: new perspectives from the real-world experience in PBC - Digital ILC 2020

View
General Hepatology
6

Intercept: FXR agonism in clinical practice: new perspectives from the real-world experience in PBC - Digital ILC 2020

View
General Hepatology
6

Intercept: FXR agonism in clinical practice: new perspectives from the real-world experience in PBC - Digital ILC 2020

View
Viral Hepatitis
5

Gilead: A NEW VIRUS IN THE MIX: Re-imagining liver disease care in the COVID-19 era - Digital ILC 2020

View
Viral Hepatitis
5

Gilead: A NEW VIRUS IN THE MIX: Re-imagining liver disease care in the COVID-19 era - Digital ILC 2020

View
Displaying 241 - 252 of 275